QT Interval Prolongation, Hydroxychloroquine, Azithromycin in Hospitalized Patients With COVID-19

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, MAY 1, 2020

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2020.1834?guestAccessKey=ecaa8580-cf8c-41f2-8a5f-1f578fbc6fc4&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050120

 

What The Study Did: This observational study examines the association of hydroxychloroquine or hydroxychloroquine and azithromycin with QT prolongation in adult patients hospitalized with coronavirus disease 2019 (COVID-19).

Authors: Howard S. Gold, M.D., of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, is the corresponding author.

 

(doi:10.1001/jamacardio.2020.1834)

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.